1. 1279. In Vitro Activity of Nacubactam (OP0595) Alone and in Combination with β-Lactams against β-Lactamase-Producing Enterobacterales Isolated in Japan. (31st December 2020) Authors: Nagira, Yu; Yamada, Keiko; Okade, Hayato; Senju, Nami; Tsutsumi, Yuko; Tabata, Yuji; Kato, Kazuhiko Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM). (26th November 2018) Authors: VanScoy, Brian D; Lakota, Elizabeth A; Bhavnani, Sujata M; Giesel, Greg; Carranco, Ana I; Nagira, Yu; Ouchi, Shohei; Kondo, Kenichiro; Ambrose, Paul G Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S422 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection. (26th November 2018) Authors: Bhavnani, Sujata M; Hammel, Jeffrey P; Lakota, Elizabeth A; VanScoy, Brian D; Nagira, Yu; Rubino, Christopher M; Sato, Nobuo; Koresawa, Tomokazu; Kondo, Kenichiro; Ambrose, Paul G Journal: Open forum infectious diseases Issue: Volume 5(2018)Supplement 1 Page Start: S427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗